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Malignant Hyperthermia

Victor L. Clark RN, BSN, CCRN
Otterbein University, Westerville, Ohio
Topic Introduction
• Malignant Hyperthermia (MH) is a rare autosomal
dominant genetic disorder that is triggered in the
presence of halogenated inhalational anesthetic gasses
and the depolarizing neuromuscular blocking agent
succinylcholine.

Underlying Pathophysiology

Incidence & Epidemiology
• Incidence of 1:10,000 to 1:250,000 anesthetics; prevalence of genetic
abnormalities may be as high as 1:400 (Rosenberg et al., 2015).
• On average, patients require three anesthetics before a crisis is
triggered (Rosenberg et al., 2015).

•

Normal Skeletal Muscle Physiology

Action potential from motor neuron travels to presynaptic terminal.

• Acetylcholine is released into the synaptic cleft and binds with the postsynaptic
skeletal muscle nicotinic membrane receptor, which then depolarizes adjacent muscle fibers.

Significance of Pathophysiology
• Dysregulation of Ca2+ in skeletal muscle causes
hypermetabolic state and high demand for ATP
(Gupta & Hopkins, 2017).
• Increased CO2 production and O2 consumption
leads to a mixed acidosis (Gupta & Hopkins, 2017).

• The first identified case of MH was in the 1960’s
when a patient with a family history of anesthesia
complications demonstrated hyperthermia, rapid heart
rate, and hypotension after induction of anesthesia
(Seifert et al., 2015).

• All ethnic groups affected in all parts of the world (Rosenberg et al.,
2015).

• Calcium (Ca2+) channels open, Ca2+ rushes into cell, and additional Ca2+ is released from the
sarcoplasmic reticulum (SR) via the ryanodine receptors (Hernandez-Ochoa & Schneider,
2018).

• MH reactions are more common in males (62%) than females (38%)
(Gupta & Hopkins, 2017).

• Normal skeletal muscle contains ryanodine receptors which regulate Ca2+ movement from
the SR to the cytoplasm of the muscle cell (Litman et al., 2018).

• Sustained muscle contraction compromises cell
membrane integrity causing hyperkalemia,
myoglobinemia, rhabdomyolysis, and acute kidney
injury (Gupta & Hopkins, 2017).

• Failure of early recognition of MH can lead to
multisystem organ failure, permanent neurological
damage, disseminated intravascular coagulopathy
(DIC), cardiac failure, and death if left untreated
(Seifert et al., 2015).

• Highest incidence of disease presentation in young adults, with a
“mean age of all patients experiencing reactions of 18.3 years old”
(Rosenberg et al., 2015).

• Ca2+ binds to troponin enabling cross-bridging of actin & myosin, causing muscle
contraction using adenosine triphosphate (ATP) to create work and heat (Gupta & Hopkins,
2017).

• Hyperthermia from high metabolic state
predisposes patient to DIC and bleeding in the
presence of invasive surgical procedures.

• Ca2+ is then removed from the cytoplasm of the cell back into the SR via the SERCA
channel to enable muscle fiber relaxation (Gupta & Hopkins, 2017). This process is collectively
known as excitation-contraction coupling (ECC).

• Hypercapnia, hyperkalemia, and tachycardia
predispose the patient to cardiac arrhythmias,
cardiovascular collapse, and death.

• A coordinated care effort is essential to recognize
and treat an MH crisis and all operating room personnel
are required to undergo MH crisis training (MHAUS,
2020).

Topic Relevance and Importance
• MH can present in patients who have previously
received anesthesia with triggering agents with no
reactions in the past (Nagelhout & Plaus, 2018, p 775).
• Presentation of signs and symptoms of MH can be of
varying magnitude and severity and mimic other
pathologic processes including neuroleptic malignant
syndrome, thyroid storm, sepsis, and
pheochromocytoma (Gupta & Hopkins, 2017). This
makes definitive diagnosis of MH difficult which can
lead to a delay in treatment and poor clinical outcomes.

Genetic Predisposition and Susceptible
Populations
• 3 genetic alterations associated with MH susceptibility: CACNA1S,
STAC3, and RYR1 genes (Litman et el., 2018).

Signs and Symptoms

• Autosomal Dominance: 50% of offspring of affected individuals inherit
genetic defect.
• All family members of a patient with known MH susceptibility must
also be considered MH susceptible until proven otherwise (MHAUS, 2020).
• Patients with certain myopathies have genetic defects associated with
MH and must be considered susceptible to MH by the anesthetist (Litman
et al., 2018):
•
•
•
•
•

Central Core Disease
Duchenne Muscular Dystrophy
Congenital Fiber Disproportion
Multiminicore Myopathy
Native America Myopathy

•
•
•
•

Becker Muscular Dystrophy
King-Denborough Syndrome
Periodic Paralysis
Centronuclear Myopathy

• Signs and symptoms can present immediately after
exposure to triggering agents up until approximately
one hour after discontinuation of triggering anesthetics
(Rosenberg et al., 2015).

Figure 2. Normal Skeletal Muscle Physiology (Hernandez-Ochoa & Schneider, 2018).

Skeletal Muscle Pathophysiology in Malignant Hyperthermia
• MH-susceptible patients demonstrate a defective ryanodine receptor (RYR1) related to
the SR in skeletal muscle cells (Rosenberg et al., 2015).
• The defective RYR1 receptor results in unopposed release of SR Ca++ stores into the
cytoplasm in the presence of triggering anesthetic agents (Litman et al., 2018).
• The SERCA channel of the SR Ca2+ sequestering mechanism becomes overwhelmed,
causing Ca2+ to build up in the skeletal muscle cell cytoplasm leading to sustained muscle
contraction (Litman et al., 2018).

• It is the responsibility of the anesthesia provider to
recognize the occurrence of MH, direct treatment, and
coordinate care with other providers to ensure optimal
clinical outcomes for patients exhibiting this rare but
life-threatening disorder.

• Sustained contraction causes increased energy use, dramatic rises in CO2 production,
increased O2 consumption, and production of heat and lactic acid (Gupta & Hopkins, 2017).

• MH can only be triggered by certain anesthetic
agents. Proper preparation and avoidance of these
triggering agents renders the likelihood of an MH crisis
occurring impossible and ensures patient safety. This
illustrates the importance of adequate preoperative
assessment including family history of unexplained
death during anesthesia. The anesthetist must have
adequate knowledge of the pathophysiologic process of
MH and take appropriate steps necessary to ensure it
does not occur.

Early Signs & Symptoms (Gupta & Hopkins, 2017)
• Sudden, unexplained rise in end-tidal carbon
dioxide (EtCO2).
• Rapid heart rate (tachycardia).
• Tachypnea in the spontaneously breathing
patient.
• Diaphoresis.
• Masseter muscle or generalized muscle rigidity.
• Unexplained fever in the immediate
postoperative period.
Late Signs & Symptoms (Gupta & Hopkins, 2017)
• Hyperthermia caused by sustained muscle
contraction.
• Lactic acidosis.
• Hyperkalemia, peaked T-waves.
• Myoglobinemia from muscle breakdown
(similar to rhabdomyolysis).
• Dark colored urine.
• Hypotension.
• Cardiac arrhythmias.
• Coagulopathies and disseminated intravascular
coagulopathy.
• Cardiovascular collapse and death.

Diagnosis
• Based on clinical presentation: unexplained
EtCO2, muscle rigidity, tachycardia, acidosis,
hyperthermia, and hyperkalemia (Rosenberg et al.,
2015).
• Gold Standard: caffeine/halothane contraction
test (CHCT)- muscle biopsy from thigh is exposed to
caffeine and/or halothane. A positive result consists
of sustained visible contraction upon exposure to
triggering agents (Gupta & Hopkins, 2017).
• CHCT is painful, expensive, and only performed
at a small amount of specialized testing centers
(Rosenberg et al., 2015).

Figure 1. Myopathies Associated with MH (Litman et al., 2018).

Figure 3. Pathologic Process of Defective RYR1 Receptor (Gupta & Hopkins, 2017).

Implications for Nurse Anesthetists
Prevention: the goal of anesthetic management of MH-susceptible patients is prevention of a
crisis, including ensuring the anesthesia machine has been properly prepared by flushing with
high-flow O2 for brand-specific timeframe, charcoal filters applied to inspiratory and expiratory
limbs of circuit if available, anesthesia gas vaporizers have been removed from the machine,
and administering no triggering agents (MHAUS, 2020).
MH-Triggering Agents:
•
•

Succinylcholine
Desflurane

•
•

Isoflurane
Sevoflurane

•

Halothane

Management of an MH Crisis:
*It is the responsibility of the anesthetist to recognize and treat an MH crisis.
• Stop administration of triggering agents.
• Alert surgeon of the need to stop
procedure.
• Hyperventilate with 100% FiO2, attach
charcoal filters to breathing circuit if
available, and change breathing circuit and
gas absorbent canister.
• Call for assistance from other anesthesia
providers.
• Give Dantrolene 2.5mg/kg initial dose,
1mg/kg as needed for persistent signs of
MH.
• Cool patient to core temperature <38.5°C
via cooling blankets, cold IV fluid, and cold
gastric/ bladder lavages as necessary.

• Insert arterial and large-bore IV/ central
line for blood pressure monitoring, frequent
lab draws, and IV fluid administration.
• IV fluids to prevent kidney injury and
cardiovascular collapse.
• Treat electrolyte & pH abnormalities.
• Treat cardiac arrhythmias as needed.
• Treat coagulopathies as needed.
• Ensure patient is monitored in critical
care unit for a minimum of 24 hours after
MH signs and symptoms are controlled.
*All management information from Gupta &
Hopkins, 2017.

Dantrolene Sodium: the only know treatment for MH works by “depressing the ECC in
skeletal muscle by binding to the RYR1 receptor and decreasing intracellular calcium
concentration” (Ratto & Joyner, 2020). Comes in two preparations:
• Dantrium™ IV (20mg dantrolene/vial;
requires 60mL sterile H2O for reconstitution).

• Ryanodex™ IV (250mg dantrolene/vial;
requires 5mL sterile water for reconstitution).

Conclusions
• Malignant Hyperthermia is a rare, autosomal dominant skeletal muscle disorder that can have
an insidious onset, difficult diagnosis, and lead to morbidity and mortality in the surgical patient.
• MH crisis-triggering agents are the depolarizing neuromuscular paralytic succinylcholine and
anesthetic gasses halothane, desflurane, sevoflurane, and isoflurane. MH can occur in patients
who have received anesthesia with these agents in the past (Nagelhout & Plaus, 2018, p 775).
• It is the responsibility of the anesthetist to perform an adequate preoperative patient history
evaluation to uncover possible MH susceptibility in the surgical patient. Patients with a family
history of MH or associated skeletal muscle disorder must be treated as MH-susceptible until
proven otherwise via CHCT at an approved facility.
• Failure to detect an MH crisis can lead to kidney failure, profound acidosis, coagulopathies,
rhabdomyolysis, cardiac dysrhythmias, cardiovascular collapse, and death (Seifert et al., 2015).
• Early detection of an MH crisis and treatment with Dantrolene affords the patient with the
greatest chance of survival in the intraoperative and postoperative period. An MH crisis requires
an adequately prepared surgical team and high level of coordinated care to ensure optimal
outcomes in patients exhibiting a malignant hyperthermia crisis.
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